ETF Managers Group’s Arbutus Biopharma ABUS Stock Holding History

ETF Managers Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$157K	Sell	51,963 -588,010	-92%	-$1.66M	0.01%	603
2022 Q4	$1.49M	Buy	639,973 +595,723	+1,346%	+$1.43M	0.07%	123
2022 Q3	$85K	Sell	44,250 -2,738	-6%	-$6.45K	﹤0.01%	654
2022 Q2	$127K	Buy	46,988 +5,957	+15%	+$15.2K	﹤0.01%	674
2022 Q1	$122K	Buy	41,031 +97	+0.2%	+$297	﹤0.01%	623
2021 Q4	$159K	Buy	40,934 +4,727	+13%	+$18.4K	﹤0.01%	620
2021 Q3	$155K	Buy	36,207 +7,756	+27%	+$25.8K	﹤0.01%	621
2021 Q2	$90K	Buy	28,451 +2,442	+9%	+$7.56K	﹤0.01%	626
2021 Q1	$82K	Sell	26,009 -15,290	-37%	-$59K	﹤0.01%	646
2020 Q4	$154K	Sell	41,299 -4,074	-9%	-$14.3K	﹤0.01%	583
2020 Q3	$144K	Buy	45,373 +24,853	+121%	+$75.6K	﹤0.01%	592
2020 Q2	$39K	Buy	+20,520	New	+$33.6K	﹤0.01%	594

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ETF Managers Group's ABUS Position: Q1 2023 in Review

ETF Managers Group reduced its Arbutus Biopharma (ABUS) stake by 92% in Q1 2023, selling an estimated $1.66M and leaving 51,963 shares worth $157K. The position accounts for 0.01% of the portfolio, ranked #603.

ETF Managers Group first reported a position in ABUS in Q2 2020 and has held it in 12 quarters since. The position peaked at $1.49M in Q4 2022. 122 funds tracked by Wall St. Rank hold ABUS as of Q1 2023.

ETF Managers Group held 51,963 shares of Arbutus Biopharma worth $157K as of Q1 2023.
ETF Managers Group sold 588,010 Arbutus Biopharma shares in Q1 2023, an estimated $1.66M.
Arbutus Biopharma made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #603 holding.
ETF Managers Group first reported a position in Arbutus Biopharma in Q2 2020 and has held it in 12 quarters since.
ETF Managers Group's Arbutus Biopharma position peaked at $1.49M in Q4 2022.
122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.